Rigel Pharmaceuticals Inc... (RIGL)
| Bid | 21.5 |
| Market Cap | 393.52M |
| Revenue (ttm) | 157.61M |
| Net Income (ttm) | 3.88M |
| EPS (ttm) | 0.27 |
| PE Ratio (ttm) | 82.74 |
| Forward PE | 18.78 |
| Analyst | Hold |
| Ask | 23.1 |
| Volume | 215,736 |
| Avg. Volume (20D) | 265,512 |
| Open | 23.01 |
| Previous Close | 23.06 |
| Day's Range | 21.93 - 23.43 |
| 52-Week Range | 7.48 - 29.82 |
| Beta | 1.34 |
About RIGL
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical t...
Analyst Forecast
According to 5 analyst ratings, the average rating for RIGL stock is "Hold." The 12-month stock price forecast is $25, which is an increase of 11.91% from the latest price.
Next Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago · seekingalpha.com
Rigel Pharmaceuticals: Realizing The Promise Of Its Acquired Pipeline AgentsRigel Pharmaceuticals has shown significant growth, particularly from the acquisition of pralsetinib, leading to a 46% improvement in stock valuation since April. Rigel's pipeline includes three appro...